Worst Biopharma CEO of 2024 Revealed: Former Cassava Sciences CEO
Beyond any doubt, Remi Barbier, the former CEO of Cassava Sciences, takes the top spot as the Worst Biopharma CEO of 2024. This decision was as clear as day for me, having made this assessment for 17 years now.
Barbier faced a tough year as Cassava’s Alzheimer’s drug candidate, simufilam, failed to show any efficacy in a significant clinical trial, leading to a blow-up within the company. As a result, he lost his job, was sanctioned by the Securities and Exchange Commission, and continues to be embroiled in ongoing legal battles with shareholders and class-action lawsuits. It’s been a rough ride for him.
If you want to dive deeper into this story, it’s available for STAT+ subscribers. But the bottom line is, Barbier’s year has been a tough one. Let this serve as a reminder of the challenges and risks that come with biopharmaceutical leadership.
